期刊文献+

70岁以上心房颤动患者109例抗栓治疗分析 被引量:9

Investigation of anti-thrombotic therapy in elderly patients over 70 years old with atrial fibrillation: report of 109 cases
暂未订购
导出
摘要 目的分析70岁以上老年心房颤动(房颤)患者治疗情况,探讨老年房颤患者抗栓治疗策略、疗效、安全性和影响因素。方法 70岁以上老年房颤患者109例,按年龄分为3组:70~79岁组(22例),80~89岁组(70例),90岁以上组(17例),回顾性分析治疗疗效、安全性和影响因素。结果所有患者中,抗栓治疗81例。单用阿司匹林30例,单用氯吡格雷34例,阿司匹林合用氯吡格雷11例,使用华法林抗凝治疗6例。70~79岁组抗血小板治疗20例(90.9%),抗凝治疗1例(4.5%);80~89岁组抗血小板治疗43例(61.4%),抗凝治疗4例(5.7%);90岁以上组抗血小板治疗12例(70.6%),抗凝治疗1例(5.9%)。房颤并存肿瘤者24例(22.0%)。既往发牛过十二指肠球部溃疡、出血性胃炎或血小板减少等出血性疾病又发生过深静脉血栓或腔隙性脑梗死等缺血性疾病的患者10例(9.2%)。抗血小板治疗中发牛深静脉栓塞、心房血栓等患者4例(5.3%),治疗后发生胃肠道出血者2例(2.7%),抗凝治疗后发生胃肠道出血、恼出血者各1例(33.3%)。结论高龄老年房颤患者抗栓治疗不充分,且存在多种复杂的病理生理状态,导致了高血栓危险和高出血风险。 Objective To investigate anti-thrombotic therapy on atrial fibrillation (AF) of elderly patients over 70 years old, including the therapeutic strategy, effect, safety and impact factors. Methods A total of 109 elderly patients with AF were analyzed retrospectively. They were divided into 3 groups by age : age 70 to 79 ( n = 22 ), age 80 to 89 ( n = 70), age over 90 ( n = 17 ). Results Among all patients, 81 cases were treated with anti-thrombotic drugs. Thirty patients were prescribed with aspirin (ASA) alone; 34 patients with clopidogrel (CPG) alone; 11 patients with ASP plus CPG; 6 patients with warfarin. Patients aged 70 to 79 with antiplatelet agents accounted for 90. 9%, while those with anticoagulant drug only 4. 5% ; Patients aged 80 to 89 with antiplatelet agents 61.4%, while those with anticoagulant drug 5.7% ; Patients aged over 90 with antiplatelet agents 70. 6% , while those with anticoagulant drug 5.9%. There were 24 cases (22. 0% ) with cancer. There were 10 patients (9. 2% ) with hemorrtlagic diseases (duodenal ulcer, hemorrhagic gastritis, thrombocytopenia, etc) as well as ischemic diseases (deep vein thrombosis, lacunar cerebral infarction, etc). In patients received antiplatelet therapy, ischemic events occurred in 4 cases (5.3%), while in patients initially treated with warfarin, the rate of bleeding events occurred in 2 cases (33. 3% ). Conclusions In elderly patients with AF, antithrombotic therapy is insufficient and the severe bleeding rate is high during anticoagulant therapy. The coexisted complicated pathophysiologic state of AF in elderly patients leads to high risk of thrombosis and bleeding events.
出处 《中国心血管杂志》 2010年第2期120-122,共3页 Chinese Journal of Cardiovascular Medicine
关键词 心房颤动 老年人 阿司匹林 氯吡格雷 华法林 Atrial fibrillation Elderly Aspirin Clopidogrel Warfarin
  • 相关文献

参考文献8

  • 1Crandall MA, Bradley DJ, Packer DL, et al. Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc, 2009, 84: 643 -662.
  • 2Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias Cardiac arrhythmias: A clinical approach. Lip GYH, Godtfredsen J, eds. Edinburgh: Mosby, 2003, 3-24.
  • 3Spence JD. Stroke: Atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol, 2009, 6: 448-450.
  • 4Levy S,Camm A J, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace, 2003, 5: 119-122.
  • 5杨帆,刘小慧,杜昕,赖沙毅.老年人非瓣膜病心房颤动患者华法林5mg起始治疗的有效性及安全性[J].中国心血管杂志,2009,14(1):31-33. 被引量:7
  • 6Perez-Gemez F, Iriarte JA, Zumalde J, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur Heart J, 2007, 28 : 996-1003.
  • 7Jacobs LG, Billett HH, Freeman K, et al. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with fails and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother, 2009, 7: 159-166.
  • 8Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging, 2009, 4: 165-177.

二级参考文献9

  • 1胡大一,周自强,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状流行病学研究[J].中国心脏起搏与心电生理杂志,2004(z1):3-6. 被引量:32
  • 2Olsson SB, Executive Steering Committee of the SPORTIF Ⅲ Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non - valvular atrial fibrillation (SPORTIF Ⅲ): randomised controlled trial. Lancet ,2003,362 : 1691-1698.
  • 3Albers GW, Diener HC, FrisonL, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvularalrial fibrillation. A randomized triM. JAMA,2005,293:690-698.
  • 4Wallentin L, Ezekowitz M, Simmers TA, et al. PETRO - investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation:a dose finding trial with comparison to warfarin. Eur Heart J, 2005,26:482.
  • 5Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation-an individual patient meta - analysis. JAMA,2002,288:2441-2448.
  • 6Roberts GW, Gallus AS, Druskeit T, et al. Comparision of an age adjusted warfarin loading protocol with empirical dosing and Fenhetty's protocol. Aust NZ J Med, 1999,29:731-736.
  • 7Eckhoff CD, Didomenico RJ, Shapiro NL. Initiating warfarin therapy: 5 mg versus 10 mg. Ann Pharmacother, 2004, 38: 2115-2121.
  • 8Hirsh J, Fuster V, Ansell J, et al. American heart Association/ American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 9孙艺红,胡大一.华法林对中国人心房颤动患者抗栓的安全性和有效性研究[J].中华内科杂志,2004,43(4):258-260. 被引量:171

共引文献6

同被引文献43

引证文献9

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部